"Our mission is to get more great science translated out of academia," says Barbara Handelin, PhD, president of BioPontis Alliance LLC, a two-year old investment group set up as a virtual network with the aim of introducing a new model for bridging the "valley of death" funding gap for early stage translational research. "We think we have the right idea at the right time," Handelin claims. "There are piles of discoveries at universities" – 6,000 annual patent disclosures according to the Association of University Technology Managers. We want to test the robustness of that discovery science then translate that discovery into something that could become a product."
Translational research deals, especially the kind that bring together industry and academia, are a hot topic in biopharma circles these...







